邓务国，男，博士,教授，博士生导师，中山大学“百人计划”引进人才，现受聘于中山大学肿瘤防治中心华南肿瘤学国家重点实验室。

1997年在北京大学获得理学博士学位(专业：生物化学和应用化学)。博士期间,主要从事黄酮类天然药物抗氧化活性及其与自由基反应机制的研究。1997-1998年,在中国人民大学化学教研室任讲师。1998-2003年,在美国德克萨斯大学休斯敦医学院(TheUniversityofTexasHealthScienceCenterMedicalSchoolinHouston)从事博士后研究,主要进行与炎症和肿瘤相关基因(COX-2/iNOS)的表达调控和分子机制等生物医学领域的研究工作。2003-2009年被聘任到美国排名第一的癌症研究和临床治疗中心-德克萨斯大学M.D.安得森癌症中心(TheUniversityofTexasM.D.AndersonCancerCenter)工作,先后任讲师(Instructor)和助理教授(AssistantProfessor),主要从事肺癌、皮肤癌、乳腺癌的基因治疗和靶向治疗;抗癌基因(FUS1和IL24)的作用机制和信号传导，以及新型肿瘤分子标记和药物治疗靶点等方面的研究,并指导博士生和博士后的科研工作。2008年至今，被聘为浙江大学客座教授。2009年9月，作为中山大学“百人计划”人才引进回国，任中山大学肿瘤防治中心华南肿瘤学国家重点实验室教授，PI和博士生导师。

近年来，本人以第一作者在Blood,CancerResearch,JBiolChem,TheFASEBJournal,Oncogene,JournalofImmunology,MelanomaResearch,CancerGeneTherapy,Circulation等国际主流杂志上发表论文20余篇,以第一作者发表SCI论文16篇，影响因子(IF)总数为131点。先后独力或共同申请主持美国NIH/NCI研究项目(SPORE,R01,P01)六项。本人是FASEBJournal,CellularandMolecularBiologyLetter,ExperimentalLungResearch等杂志的审稿人;美国癌症研究协会(AACR)、美国生物化学和分子生物学(ASBMB)会员。

本人的研究兴趣和目前的主要研究方向：（1）肺癌、皮肤癌和乳腺癌的发生、发展和转移的信号传导及分子机理;(2)癌症的基因治疗,分子靶向治疗和结合治疗,以及这些治疗的分子机制和临床应用；（3）抗癌基因(如FUS1,IL-24,NPRL2,FHIT，p53)和致瘤基因(如COX-2，iNOS，AP-2β,CD70)的表达调控、信号转导和分子机制;(4)利用最近发展的基因组学和蛋白质组学技术(如PCRArray,siRNAlibraryscreen,SELID-MSandLC-MS-basedProteinChipArrays)筛选,发现和鉴定新型的肿瘤分子标记和药物治疗靶点;(5)新型多功能抗癌纳米药物(基因纳米药物和多肽纳米药物)的研究开发,以及它们在癌症治疗和检测上的临床应用。

[已发表的代表性SCI论文]
1.DengWG,KwonJ,EkmekciogluS,PoindexterNJ,GrimmEA.IL-24genetransfersensitizesmelanomacellstoerlotinibthroughmodulationoftheApaf-1andAktsignalingpathway.MelanomaRes.(inpress),2009.
2.DengWG,WuG,UedaK,XuK,RothJA,JiL.EnhancementofantitumoractivityofcisplatinbytumorsuppressorFUS1inhumanlungcancercells.CancerGeneTher.15:29-39,2008.
3.DengWG,KawashimaH,WuG,JayachandranJ,XuK,MinnaJD,RothJA,JiL.SynergistictumorsuppressionbycoexpressionofFUS1andp53isassociatedwithdownregulationofMDM2andactivationofApaf1-dependentapoptoticpathwayinhumannon-smallcelllungcancercells.CancerRes.67:709-17,2007.
4.DengWG,MonteroA,WuKK.Interferon-gammasuppressesCOX-2promoteractivitybyinhibitingc-JunandC/EBP?binding.Arterioscler.Thromb.Vasc.Biol.27:1752-1759,2007.
5.DengWG,JayachandranG,XuK,RothJA,JiL.Tumor-specificactivationofhumantelomerasereversetranscriptase(hTERT)promoteractivitybyactivatingenhancer-bindingprotein-2?(AP-2?)inhumanlungcancercells.J.Biol.Chem.282:26460-70,2007.
6.DengWG,NishizakiM,KagawaS,FangB,RothJA,JiL.InductionofapoptosisbyFHITgeneviaactivationofdeathreceptorandcaspasecascadesignalingpathwayinhumannon-smalllungcancercells.Biochem.Biophys.Res.Commun.355:993-999,2007.
7.LinJ,SunT,JiL,DengW,RothJA,MinnaJ,ArlinghausR.Oncogenicactivationofc-Ablinnon-smallcelllungcancercellslackingFUS1expression:Inhibitionofc-AblbythetumorsuppressorgeneproductFus1.Oncogene26:6989-96,2007.
8.OhtaniS,UedaK,DengW,WuG,JayachandranG,IwamaruA,KondoS,AtkinsonEN,MinnaJD,RothJA,JiL.Acombinationtreatmentwithcandidate3p21.3tumorsuppressor101F6-nanoparticleandascorbicacidpromotessynergisticandselectiveinhibitionofhumanNSCLCgrowthviacaspase-independentapoptosisandautophagiccelldeath.CancerRes.67:6293-6303,2007.
9.DengWG,TangSZ,TsengHP,WuKK.Melatoninsuppressesmacrophagecyclooxygenase-2andinduciblenitricoxidesynthaseexpressionbyinhibitingp52acetylationandbinding.Blood108:518-24,2006.
10.*CieslikKA,*DengWG,(*co-firstauthor),WuKK.EssentialroleofC-Relinnitricoxidesynthase-2transcriptionalactivation:time-dependentcontrolbysalicylate.Mol.Pharmacol.70:2004-14,2006
11.UedaK,KawashimaH,OhtaniS,DengW,RavooriM,BanksonJ,GaoB,GirardL,MinnaJD,RothJA,KundraV,JiL.The3p21.3TumorsuppressorNPRL2playsanimportantroleincisplatin-inducedresistanceinhumannon-small-celllungcancercells.CancerRes.66:9682-90,2006.
12.DengWG,ZhuY,WuKK.Roleofp300andPCAFinregulatingcyclooxygenase-2promoteractivationbyinflammatorymediators.Blood103:2135-42,2004.
13.DengWG,ZhuY,WuKK.Up-regulationofp300bindingandp50acetylationintumornecrosisfactor-alphainducedcyclooxygenase-2promoteractivation.J.Biol.Chem.278:4770-77,2003.
14.DengWG,WuKK.Regulationofnitricoxidesynthaseexpressionbyp300coactivatorandp50NF-?Bacetylation.J.Immunol.171:6581-88,2003.
15.DengWG,ZhuY,MonteroA,WuKK.QuantitativeanalysisofbindingoftranscriptionfactorcomplextobiotinylatedDNAprobebyatreptavidin-agarosepulldownassay.Anal.Biochem.323:12-8,2003.
16.DengWG,SaundersM,HeXZ,YehH,WuKK.Identificationofcyclooxygenase-2andangiogenesissuppressingfactorproducedbyhumanfibroblasts.FASEBJ.16:1286-98,2002.
17.ZhuY,SaundersM,YehH,DengWG,WuKK.Dynamicregulationofcyclooxygenase-2promoteractivitybyisoformsofCCAAT/enhancer-bindingprotein.J.Biol.Chem.277:6923-28,2002.
18.SchroerK,ZhuY,SaundersM,DengWG,XuXM,Meyer-KirchrathJ,Wu,KK.Obligatoryroleofcyclicadenosinemonophosphateresponseelementincyclooxygenase-2promoterinductionandfeedbackregulationbyinflammatorymediators.Circulation105:2760-65,2002.
19.DengWG,RuanKH,DuM,SaundersM,WuKK.AspirinandsalicylatebindtoBiPandinhibititsATPaseactivityinhumanfibroblasts.FASEBJ.15:2463-70,2001.
20.*LiouJY,*DengWG,(*co-firstauthor),GilroyDK,WuKK.Colocalizationandinteractionofcyclooxygenase(COX-2)andcaveolin-1inhumanfibroblasts.J.Biol.Chem.276:34975-82,2001.
21.DengWG,HeYK,FangXW,WuJL.Radiolysisofrutininaeratedethanolicsolution.Radiat.Phys.Chem.53:629-33,1998.
22.DengWG,FangXW,WuJL.Flavonoidsfunctionasantioxidants:byscavengingreactiveoxygenspeciesorbychelatingiron?Radiat.Phys.Chem.50:273-5,1997.
23.YiQM,DengWG,XiaZP.PolymorphismandgeneticrelationshipamongwildandcultivatedricespeciesdeterminedbyAP-PCRanalysis.Hereditas122:135-41,1995.

[已发表的国际学术会议摘要]
　1.DengW,KwonJ,Grimm,EA.CombinationtherapywithIL-24andtyrosinekinaseinhibitors:Anewpromisingtherapeuticstrategiesforthetreatmentofhumanmelanoma.AmericanAssociationforCancerResearch(AACR)100thAnnualMeeting,Denver,CO,April18,2009.Proc.Am.Assoc.CancerRes.50:820,2009.
　2.DengW,KawashimaH,RothJA,JiL.TumorsuppressorFUS1sensitizesresponsetogefitinibtreatmentandovercomeschemoresistanceviainactivationoftheAKT/METsignalingpathwayinhumanlungcancercellsAmericanAssociationforCancerResearch(AACR)99thAnnualMeeting,SanDiego,CA,April12-16,2008.Proc.Am.Assoc.CancerRes.49:2008.
　3.JayachandranG,DengW,MinnaJD,RothJA,JiL.BystandereffectsinFUS1-nanoparticle-mediatedhumanlungcancergenetherapy.AmericanAssociationforCancerResearch(AACR)99thAnnualMeeting,SanDiego,CA,April12-16,2008.Proc.Am.Assoc.CancerRes.49:2008.
　　4.DengW,UnoF,WuG,KawashimaH,RothJA,JiL.Nanoparticle-mediateddeliveryoftherapeuticpeptidederivedfromnoveltumorsuppressorFUS1proteinforhumanlungcancertreatment.AmericanAssociationforCancerResearch(AACR)98thAnnualMeeting.LosAngeles,CA,April,2007.Proc.Am.Assoc.CancerRes.48:1334,2007.
　　5.IwamaruA,DengW,KawashimaH,RothJA,JiLInteractionoftumorsuppressorFUS1withnuclearreceptortyrosinekinaseRAR-?proteinsenhancesthesensitivityofnon-smallcelllungcancer(NSCLC)toretinoid-mediatedtherapy.AmericanAssociationforCancerResearch(AACR)98thAnnualMeeting.LosAngieles,CA,April,2007.Proc.Am.Assoc.CancerRes.48:985,2007.
　　6.DengW,JayachandranG,XuK,RothJA,JiL.Tumor-specificactivationofhTERTpromoteractivitybytheAP-2betatranscriptionfactorinhumanlungcancercells.AmericanAssociationforCancerResearch(AACR)97thAnnualMeeting.Washington,DC,April,2007.Proc.Am.Assoc.CancerRes.47:929,2006.
　　7.WuG,DengW,JayachandranG,MinnaJD,RothJA,JiL.InteractionofthetumorsuppressorFUS1withPDGFRbetainhibitsPDGFR-mediatedproliferationofhumanlungcancercells.AmericanAssociationforCancerResearch(AACR)97thAnnualMeeting,Washington,DC,April,2006.Proc.Am.Assoc.CancerRes.47:344,2006.
　　8.KawashimaH,JayachandranG,DengW,Xu,K,MinnaJD,RothJA,JiL.OvercominggefitinibresistanceinNSCLCviainactivationofthePI3K/AKTsignalingpathwaybyacombinationoftheFUS1nanoparticlesandEGFRinhibitors.AmericanAssociationforCancerResearch(AACR)97thAnnualMeeting,Washington,DC,April,2007.Proc.Am.Assoc.CancerRes.47:1274,2006.
　　9.DengW,UnoF,MinnaJD,RothJA,JiL.SynergistictumorsuppressionbycoexpressionofFUS1andp53concurrenceswithFUS1-mediateddownregulationofMDM2,accumulationofp53,andactivationofApaf1-dependentapoptoticpathwayinhumanNSCLCcells.AmericanAssociationforCancerResearch(AACR),96thAnnualMeeting,Anaheim,CA,April,2005.Proc.Am.Assoc.CancerRes.46:828,2005.
　　10.WuG,DengW,KundraV,FangB,RothJA,JiL.AnovelsynthetichTERT-Mini-CMVchimerapromoter-driventumor-selectiveandhigh-efficiencyexpressionoftransgeneforsystemiccancergenetherapy.AmericanAssociationforCancerResearch(AACR),96thAnnualMeeting,Anaheim,CA,April,2005.Proc.Am.Assoc.CancerRes.46:791,2005.
　　11.UedaK,KawashimaH,DengW,MinnaJD,RothJA,JiL.Inactivationofthepotential3p21.3tumorsuppressorNPRL2significantlycorrelateswiththecisplatin-inducedresistanceinhumanNSCLCcells.AmericanAssociationforCancerResearch(AACR),96thAnnualMeeting,Anaheim,CA,April,2005.Proc.Am.Assoc.CancerRes.46:350,2005.
　　12.DengW,WuKK.AugmentationofNF-?Bmediatedgeneexpressionbyapositivep300andp50regulatoryloop.TheExperimentalBiology(EB)2003MeetingAbstracts,SanDeigo,CA,April,2003.
　　13.DengW,WuKK.Roleofp300coactivatorandhistoneacetyltransferaseinCOX-2transcriptionalactivation.The4thWinterEicosanoidConferenceAbstracts,Baltimore,MA,March,2002.
　　14.DengW,ShtivelbandMI,WuKK.Controlofcancer-inducedangiogenesisbyanendogenousfactor.The44thAmericanSocietyofHematologyAnnualMeetingAbstracts,Philadephia,PA,December,2002.

[在美国参加的国际学术会议及所作的学术报告]
　　1.NovelcombinationofIL-24moleculartherapywithtyrosinekinaseinhibitors:Anewpromisingtherapeuticstrategiesforthetreatmentofhumanmelanoma.TheAmericanAssociationforCancerResearch(AACR)2009100thAnnualMeeting,Denver,CO,USA,April18-22,2009.(Poster)
　　2.IL-24/MDA-7nanoparticlesincombinationwithtyrosinekinaseinhibitorsenhancesinhibitionofhumanmelanomaviaApaf-1andAkt–dependentsignalingpathways.TheAmericanAssociationforCancerResearch(AACR)SpecialMeeting:InfectionandCancerTherapeutics,HongKong,China,December7-11,2008.(Poster)
　　3.CombinationtreatmentwithFUS1nanoparticlesandEGFRinhibitorsforlungcancer.The99thAmericanAssociationforCancerResearch(AACR)2008AnnualMeeting,SanDiego,CA,USAApril12-16,2008.(Oral)
　　4.BystandereffectsinFUS1-nanoparticle-mediatedhumanlungcancergenetherapy.The99thAmericanAssociationforCancerResearch(AACR)2008AnnualMeeting,SanDiego,CA,USAApril12-16,2008.(Poster)
　　5.Developmentofnoveldeliverysystemsfortherapeuticpeptideforhumanlungcancertreatment.The98thAmericanAssociationforCancerResearch(AACR)2007AnnualMeeting,LosAngeles,CA,USAApril14-18,2007.(Poster)
　　6.InteractionoftumorsuppressorFUS1withnuclearreceptortyrosinekinaseRAR-?proteins.The98thAmericanAssociationforCancerResearch(AACR)2007AnnualMeeting,LosAngeles,CA,USA,April　14-18,2007.(Oral)
　　7.DiscoveryofnovelcancerbiomarkersandtherapeutictargetsassociatedwithhTERTpromoterinhumanlungcancercells.The97thAmericanAssociationforCancerResearch(AACR)AnnualMeeting,Washington,DC,USA,April1-5,2006.(Oral)
　　8.InteractionoftumorsuppressorFus1withPDGFRbetainhibitsPDGFR-mediatedproliferationofhumanlungcancercells.The97thAmericanAssociationforCancerResearch(AACR)AnnualMeeting,Washington,DC,USA,April1-5,2006.(Poster)
　　9.OvercominggefitinibresistanceinNSCLCviainactivationofthePI3K/AKTsignalingpathwaybyacombinationofFUS1nanoparticlesandEGFRinhibitors.The97thAmericanAssociationforCancerResearch(AACR)AnnualMeeting,Washington,DC,USA,April1-5,2006.(Poster)
　　10.SynergistictumorsuppressionbycoexpressionofFUS1andp53inhumanlungcancercells.The96thAmericanAssociationforCancerResearch(AACR)AnnualMeeting,Anaheim,CA,USA,April16-20,2005.(Poster)
　　11.AnovelsynthetichTERT-Mini-CMVchimerapromoter-driventumor-selectiveandhigh-efficiencyexpressionoftransgeneforsystemiccancergenetherapy.The96thAmericanAssociationforCancerResearch(AACR)AnnualMeeting,Anaheim,CA,USA,April16-20,2005.(Poster)
　　12.Inactivationofthepotential3p21.3tumorsuppressorNPRL2significantlycorrelateswiththecisplatin-inducedresistanceinhumanNSCLCcells.The96thAmericanAssociationforCancerResearch(AACR)AnnualMeeting,Anaheim,CA,USA,April16-20,2005.(Oral)
　　13.AugmentationofNF-?Bmediatedgeneexpressionbyapositivep300andp50regulatoryloop.TheExperimentalBiology(EB)2003Meeting,SanDiego,CA,USA,April11-15,2003.(Poster)
　　14.RegulationofCOX-2andiNOSgenebyp300bindingandNF-?Bp50acetylation.TheSpecialPostdoctoralProgramforAmericanSocietyforBiochemistryandMolecularBiology(ASBMB)TravelAwardeesattheExperimentBiology2003Meeting,SanDiego,CA,USA,April13,2003.(Poster)
　　15.Controlofcancer-inducedangiogenesisbyanendogenousfactor.The44thAmericanSocietyofHematologyAnnualMeeting,Philadelphia,PA,USA,December7-10,2002.(Oral)
　　16.Roleofp300coactivatorandhistoneacetyltransferaseincyclooxygenase-2transcriptionalactivation.The4thWinterEicosanoidConference,Baltimore,ML,USA,March10-13,2002.(Oral)